Jefferies has lowered its peak sales forecast for Merck's experimental eye drug remigromig by 60%, citing trial results that showed it was less effective and had more safety issues than the established treatment Lucentis. The drug met non-inferiority but showed smaller vision improvements and higher rates of adverse effects like proliferative diabetic retinopathy. Despite this, Jefferies kept a buy rating on Merck, noting remigromig might still help patients unresponsive to current treatments. The market awaits results from another trial, BAROLO, expected in March 2027.
Merck & Co., Inc. (MRK) shares are trading at USD 145.24 on Pluang as of Oct 12, 2026 23:31 WIB, showing a slight decline of 0.25% in one day. The stock's market capitalization stands at $359.22 billion, reflecting its significant presence in the health sector. Investors typically hold MRK shares for about 99 days on Pluang, indicating moderate-term interest in the company despite recent trial concerns.
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
Novavax shares surged 16%, leading a biotech sector rally alongside Moderna's 11% gain and Merck's 3% rise. The spike occurred without any new company-specific announcements, driven by a broad sector-wide bid in vaccine and biotech stocks. Novavax's ...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
The global market for Dipeptidyl Peptidase-4 (DPP-4) inhibitors, used in type 2 diabetes treatment, is projected to grow from $11.28 billion in 2025 to $15.53 billion by 2032, at a CAGR of 5.47%. Growth is fueled by the ongoing global burden of type ...
On October 7, HP, Merck, and Seagate each paid their quarterly dividends, highlighting different approaches to rewarding shareholders. Merck paid the highest dividend per share at $0.85, reflecting its strong pharmaceutical business and growth, despi...
